ADVERTISEMENT

NPPA fixes price caps for 12 anti-diabetic medicines

October 25, 2021 11:03 pm | Updated 11:03 pm IST - New Delhi

NPPA fixed the ceiling prices for 12 anti-diabetic generic medicines, including glimepiride tablets, glucose injection and intermediate acting insulin solution.

Drug price regulator National Pharmaceutical Pricing Authority (NPPA) on Monday said it has fixed the ceiling prices for 12 anti-diabetic generic medicines, including glimepiride tablets, glucose injection and intermediate acting insulin solution.

In a tweet, the drug price regulator said, “To make it possible for every Indian to afford medical treatment against diseases like diabetes, NPPA has initiated a successful step by fixing the ceiling prices of 12 anti-diabetic generic medicines.” These include glimepiride tablet of strength 1 mg, with ceiling price at ₹3.6 per tablet, while that for 2 mg is ₹5.72 per tablet.

The ceiling price of 1 ml glucose injection of 25% strength has been fixed at 17 paise, while that of 1ml of insulin (soluble) injection of strength 40IU/ml is ₹15.09.

ADVERTISEMENT

Similarly, 1 ml of intermediate acting (NPH) solution insulin injection of strength 40 IU/ml has a ceiling price of ₹15.09, and that of 1 ml of premix insulin 30:70 injection (regular NPH) injection of strength 40 IU/ml is also ₹15.09.

NPPA further said the ceiling price of metformin immediate release tablet of strength 500 mg has been fixed at ₹1.51 per tablet, while that of 750 mg strength is at ₹3.05 per tablet and 1,000 mg strength at ₹3.61 per tablet.

For metformin control release tablet of strength 1000 mg, the ceiling price is ₹3.66 per tablet, NPPA said, adding the same for 750 mg strength is ₹2.4 per tablet and ₹1.92 per tablet for metformin control release tablet of strength 500 mg.

ADVERTISEMENT

This is a Premium article available exclusively to our subscribers. To read 250+ such premium articles every month
You have exhausted your free article limit.
Please support quality journalism.
You have exhausted your free article limit.
Please support quality journalism.
The Hindu operates by its editorial values to provide you quality journalism.
This is your last free article.

ADVERTISEMENT

ADVERTISEMENT